The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zaldumbide, A.
Right arrow Articles by Boulukos, K. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zaldumbide, A.
Right arrow Articles by Boulukos, K. E.
The Journal of Immunology, 2002, 169: 4873-4881.
Copyright © 2002 by The American Association of Immunologists

The Role of the Ets2 Transcription Factor in the Proliferation, Maturation, and Survival of Mouse Thymocytes1

Arnaud Zaldumbide, Françoise Carlotti, Philippe Pognonec and Kim E. Boulukos2

Institute of Signaling, Developmental Biology and Cancer Research, Center de Biochimie, Université de Nice, Parc Valrose, Nice, France


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
In this study, we investigated the effects of Ets2 expression on the proliferation, maturation, and survival of thymocytes by establishing transgenic mice that specifically express Ets2 or a dominant negative form of Ets2, {Delta}ets2, in the thymus. We show that, in young animals, there are fewer T cells in {Delta}ets2 transgenic thymi and that the maturation of these T cells is affected at the CD4-CD8- double-negative to CD4+CD8+ double-positive transition compared with wild-type littermate mice. Partial recovery in the number of thymocytes and full T cell maturation are restored with increasing age of {Delta}ets2 transgenic animals. However, thymocytes from adult {Delta}ets2 transgenic mice cultured ex vivo are more sensitive to cell death and to glucocorticoid-induced apoptosis than are T cells from control littermate mice. We also show that T cells from adult ets2 transgenic mice proliferate faster than their wild-type littermates. The proliferation and survival of these T cells are clearly affected upon apoptotic signals: glucocorticoid-induced apoptosis induces T cells from ets2 transgenic mice to continue to proliferate in vivo and to survive better ex vivo than T cells from control littermates. It has been shown that c-Myc expression is required for thymic proliferation and improves thymocyte survival of dexamethasone-treated animals. We show that the expression of c-Myc, an Ets2 target, is elevated in T cells freshly isolated from thymi of ets2 transgenic mice pretreated with dexamethasone. Together, these results show that Ets2 plays a role in the proliferation and survival of thymocytes, implicating a Myc-dependent pathway.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
The transcription factor Ets2 was first identified by its homology to v-Ets (1, 2) of the erythroid-myeloid transforming E26 avian retrovirus (3, 4). Ets2 is a member of the ets family of transcription factors with ~30 members described to date (reviewed in Ref. 5). Based on amino acid sequences, several Ets subgroups have been identified and Ets2 is classed with it most closely related member, Ets1, the progenitor to v-Ets. Both Ets1 and Ets2 are implicated in regulating genes involved in proliferation, differentiation, apoptosis (reviewed in Refs. 5 and 6), and senescence processes (7), suggesting the importance of these two proteins in cells. Indeed, ets2 gene disruption studies resulted in early embryonic lethality (8), and disruption of the ets1 gene leads to 50% mortality around birth and the absence of NK and NK T cells (9, 10). Because gene knockouts can often be compensated by redundant family members or redundant signaling pathways, transgenic studies expressing proteins in specific tissues help elucidate functions of different proteins.

During T cell development, precursor cells exit the bone marrow and migrate to the thymus where these cells differentiate into mature thymocytes through a highly ordered series of proliferation and maturation events. These events are characterized by the expression of CD4 and CD8 coreceptors. Immature T cells that are CD4-CD8- double-negative (DN)3 mature to an intermediate CD4+CD8+ double-positive (DP) stage and terminate into mature CD4+CD8- or CD4-CD8+ single-positive (SP) T cells. Thymocytes bearing functional TCRs are positively selected and differentiate into fully functional T cells. The remaining cells undergo negative selection and die by apoptosis. Therefore, the thymus is an excellent in vivo model for studying cellular processes of proliferation, differentiation, and apoptosis.

Several articles showed that Ets2 and Ets1 are expressed during T cell development (11, 12, 13). By RT-PCR, it was shown that both ets2 and ets1 mRNAs are expressed at constant levels throughout T cell development with increasing expression of both transcripts at the pre-T DP stage (13). However, Western analysis indicated that Ets1 protein is abundantly expressed in DN and SP T cell subpopulations, whereas expression of the Ets2 protein is at the DP stage (12). This reciprocal expression suggests that Ets1 and Ets2 proteins have distinct roles during T cell development. Mouse model studies have addressed only the role of Ets1, not that of Ets2, in thymic development. Ets1 was shown to influence T cell development by affecting both cellularity and maturation at the DN to DP transition in recombination-activating gene (RAG)2-/- complementation studies (14, 15). In addition, T cell defects were observed for TCR-mediated proliferation (15). Furthermore, gene disruption experiments used to generate ets1 knockout mice indicate that the loss of Ets1 results in T cell activation defects and that Ets1 is clearly required for NK and NK T cells (9, 10).

In this study, we investigated the effects of Ets2 expression on cell proliferation, maturation, and survival in the thymus. We established transgenic mice that specifically express Ets2 or a dominant negative form of Ets2 ({Delta}ets2), which competes with endogenous Ets2 at the DP stage. We show that the {Delta}ets2 transgene affects the number and maturation of thymic cells in young animals. As {Delta}ets2 transgenic mice reach adulthood, normal T cell development is observed, although cell numbers are only partially recovered. However, thymocytes from adult {Delta}ets2 transgenic mice cultured ex vivo are more sensitive to cell death and glucocorticoid-induced apoptosis than are T cells from control littermate mice. In addition, we find that Ets2 expression allows thymocytes to proliferate and survive better upon the induction of apoptotic signals. We show that c-Myc, an Ets2 target gene, is up-regulated in rapidly proliferating Ets2-expressing thymocytes pretreated with dexamethasone, demonstrating that Ets2 plays a role in proliferation and survival of thymocytes probably via a Myc-dependent pathway.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Generation of transgenic mice

We cloned 2.1 kb of the human full length ets2 cDNA into p1017 vector (16) consisting of the lck proximal promoter, the human growth hormone genomic sequence, and a poly(A)+ site to generate lckPr-ets2 transgenic mice. A second construct of 1.1 kb corresponding to the DNA binding domain of Ets2 and functioning as a dominant negative mutant (17) was also cloned into p1017 to generate lckPr-{Delta}ets2 transgenic mice. After microinjection of each construct into C57BL/6 DBA eggs and reimplantation into foster females, several founder lines were obtained by Service d’Experimentation Animale et de Transgenèse (VilleJuif, France). Two families for each construct were further analyzed and characterized. lckPr-ets2 and lckPr-{Delta}ets2 mice were backcrossed at least four times with C57BL/6 mice to generate over a 96.8% C57BL/6 background. Mice were maintained in a pathogen-free animal facility at the Université de Nice (Nice, France). We used the MICE software (pognonec@unice.fr) to follow the different transgenic families and their generations (18).

Cell analysis

Single cell suspensions were obtained by washing thymi in sterile PBS and disrupting the tissue on nylon meshes with tips of plungers of sterile 1-ml syringes. Cells were washed and centrifuged in PBS, and single cell suspensions were counted on a hemocytometer by trypan blue exclusion. R-PE-conjugated rat anti-mouse CD4 (L3T4), and FITC-conjugated CD8a (Ly-2) mAbs were purchased from BD PharMingen (San Diego, CA). Cells (1 x 106) were washed in PBS containing 0.1% BSA; cells were incubated in 100 µl of PBS/0.1% BSA with 5 µg/ml Abs for 30 min at 4°C in the dark. Cells were then washed in PBS containing 0.1% BSA, fixed in PBS plus 1% formaldehyde, and 10,000–20,000 events were analyzed on a FACSCalibur flow cytometer (BD Biosciences, Mountain View, CA).

Cell viability was determined by plating cells at 106 cells/ml in RPMI 1640 supplemented with 10% FCS. For in vitro induction of apoptosis, dexamethasone at 0.1 µM was added to freshly isolated cells. The vehicle, DMSO, was added to controls. Cell numbers were determined by counting on a hemocytometer by trypan blue exclusion at each time point indicated in Results.

In vivo proliferation was determined by injecting i.p. 1 mg of 5-bromo-2'-deoxyuridine (BrdU) diluted in PBS. Animals were sacrificed 4 h later and thymocytes were obtained as described above. Thymocytes (5 x 106) were washed in PBS containing 0.1% BSA, and then permeabilized and fixed overnight at 4°C in 2% paraformaldehyde 0.01% Tween. Cells were washed in PBS with 0.1% BSA, resuspended in DNase buffer (150 mM NaCl, 4.2 mM MgCl2, and 10 µ1 1 M HCl), and incubated with 50 U of DNase I for 30 min at 37°C. Cells were again washed in PBS, incubated with 20 µl of anti-BrdU-FITC-conjugated Ab (no. 347583; BD Biosciences) in 80 µl of PBS/Tween for 30 min at room temperature, and then diluted in 1 ml of PBS for analysis by FACS.

In vivo induction of apoptosis was performed by i.p. injections of mice with 2.5 mg of dexamethasone diluted in PBS. Forty-eight hours later, mice were sacrificed and thymocytes obtained as described above. T cells from thymi were then incubated with CD4 and CD8a mAbs as described above.

Expression of transgenes

For slot blot analysis, DNA was obtained from mouse tails, following proteinase K/SDS phenol chloroform extraction and ammonium acetate precipitation, and loaded in triplicate onto nitrocellulose membranes. Membranes were then hybridized to a 32P-labeling ets2 gel-purified fragment.

For Southern analysis, 10 µg of DNA was digested with the EcoRI restriction enzyme, and then the digested DNA was fractionated by electrophoresis on 0.8% agarose gels. After transfer, hybridization was performed as described by the manufacturer. Copy numbers were determined by comparing dilutions of 0.78–50 pg of the original plckPr-ets2 plasmid digested with EcoRI. The values from 6.25 to 50 pg were graphed to calculate the numbers of copies using the MacBAS program (data not shown).

For Western blot analysis, freshly prepared thymocytes from untreated or dexamethasone-treated animals were lysed, and 40 µg of total protein from each lysate in Laemmli buffer was electrophoresed on either 10 or 15% polyacrylamide-bisacrylamide gels. Migrated proteins were then transferred to polyvinylidene difluoride membranes as described by the manufacturer (DuPont-NEN, Boston, MA), immunoblotted with Ets2 (Santa Cruz (sc)-351), Ets1 (sc-350), c-Myc (sc-764), Bcl-x (sc-634), Bcl-2 (sc-492-G) and {beta}-tubulin (tub2.1; Sigma-Aldrich, St. Louis, MO) Abs, and revealed by ECL as described by the manufacturer.

Morphology

Histological staining was performed by fixing thymi with 10% paraformaldehyde overnight at 4°C. A series of 60-min dehydration steps was performed by increasing ethanol concentrations from 30, 50, 70, to 90%, followed by three incubations with 100% ethanol. The thymi were then placed in a mixture of active resine (50%) and ethanol (50%) at 4°C overnight. Then thymi were placed in 100% active resine to which the hardener was added. Slices (5–10 µm) were obtained using a microtome. After transfer to glass slides, slices were stained with hematoxylin, rinsed in water, dried at 70°C, and mounted with Eukitt (EMS, Fort Washington, PA).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Recent studies by RT-PCR have shown that both ets1 and ets2 are detected in all stages of T cell development from pro-T cells that have not yet been committed to the T cell lineage to mature peripheral CD4+CD8- helper or CD4-CD8+ killer cells in peripheral tissues (13). The highest expression of both ets1 and ets2 mRNA is found in the DP pre-T cell population where TCR{beta} has already been rearranged and TCR{alpha} is undergoing rearrangement (summarized in Fig. 1Go). Although both transcripts are similarly expressed throughout T cell development in the thymus, Ets1 and Ets2 proteins are differentially expressed. Ets1 is found in CD4-CD8- DN cells and CD4+CD8- and CD4-CD8+ SP cells, whereas Ets2 protein is specifically expressed in CD4+CD8+ DP T cells (12).



View larger version (28K):
[in this window]
[in a new window]
  		FIGURE 1. Summary of the expression of ets2 and ets1 during T cell development. Schematically represented are the different maturation steps of T cells in the thymus and secondary lymphoid tissues. These results of ets2 and ets1 mRNA expression are summarized based on semiquantitative RT-PCR studies from Anderson (13 ).

 
To determine the role of Ets2 during thymic development, transgenic mice were generated. Visualized schematically in Fig. 2GoA are the two different constructs used to obtain transgenic mice. The first construct, corresponding to the full length human ets2 cDNA under the control of the lck proximal promoter, was used to generate lckPr-ets2 transgenic mice. The second construct, {Delta}ets2, corresponding to the DNA binding domain of Ets2, which functions as a competitor of Ets2, cloned downstream of the lck proximal promoter, was used to generate lckPr-{Delta}ets2 transgenic mice. The proximal lck promoter is active beginning at the DN to DP transition and remains active throughout T cell development (see Ref. 19). Southern analysis was performed to confirm the integration of the transgenes. As predicted, digesting mouse-tail DNAs from lckPr-ets2 transgenic mice with the restriction enzyme EcoRI gives a doublet of 2.2 and 2.1 kb corresponding to the full length ets2 and hGH, respectively, using a probe containing ets2 and hGH sequences (data not shown), or a band at 2.2 kb using an ets2-specific probe (Fig. 2GoB). Sizes of 1.5 and 2.1 kb corresponding to {Delta}ets2 and hGH, respectively, were obtained using a probe containing both ets2 and hGH sequences (data not shown) or a band of 1.5 kb using an ets2-specific probe (Fig. 2GoB) following EcoRI digestions of tail DNAs from lckPr-{Delta}ets2 transgenic mice. Two families expressing either ets2 or {Delta}ets2 transgenes were used for further studies. Western analysis confirmed the expression of Ets2 with an apparent molecular mass of 60 kDa and of {Delta}Ets2 with an apparent molecular mass of 16 kDa (Fig. 2GoC) in two different families of lckPr-ets2 and of lckPr-{Delta}ets2 transgenic mice, respectively.



View larger version (29K):
[in this window]
[in a new window]
  		FIGURE 2. The different constructs used to generate transgenic mice and their analyses by Southern and Western. A, Visualized schematically are the two different constructs used to obtain transgenic mice. The first construct corresponds to the full length human ets2 cDNA cloned downstream of the lck proximal promoter and was used to generate lckPr-ets2 transgenic mice. The second construct corresponds to a dominant negative form of Ets2, {Delta}ets2, cloned downstream of the lck proximal promoter and was used to generate lckPr-{Delta}ets2 transgenic mice. Digesting mouse-tail DNAs from lckPr-ets2 transgenic mice with the restriction enzyme EcoRI predicts a doublet of 2.2 and 2.1 kb corresponding to the full length ets2 and hGH, respectively, when using an ets2-hGH fragment as a probe. Sizes of 1.5 and 2.1 kb corresponding to {Delta}ets2 and hGH, respectively, should be obtained following EcoRI digestions of tails from lckPr-{Delta}ets2 transgenic mice. An ets2 fragment used as a probe will generate a 2.2 and 1.5 kb band from EcoRI-digested tails from lckPr-ets2 and lckPr-{Delta}ets2 transgenic animals, respectively. , Coding sequence corresponding to the Ets DNA binding domain (DBD). B, Southern analysis of ets2 and {Delta}ets2 transgenes. EcoRI digestions of tail DNAs isolated from different lckPr-ets2 or lckPr-{Delta}ets2 transgenic families were performed, and DNAs were migrated on 0.8% agarose gels. Migrated DNAs were transferred onto nitrocellulose membranes and hybridized to ets2 probe isolated and gel purified from the plck-ets2 plasmid. As predicted above, a band of 2.2 kb corresponding to the full length ets2, and band of 1.5 kb corresponding to {Delta}ets2, were obtained using an ets2 specific probe and are indicated. The number of ets2 or {Delta}ets2 transgenes are 7 copies and 20 copies, respectively. Two families expressing either ets2 or {Delta}ets2 transgenes were used for further studies. C, Western analysis of transgenic mice. Total cell lysates from thymi of transgenic mice were run on 10–15% acrylamide gels. Following transfer to nylon membranes, expression of the different ets2 transgene families were determined using Ets2-specific Abs. Proteins with apparent molecular mass of 60 kDa, corresponding to Ets2, and 16 kDa, corresponding to {Delta}Ets2, are visualized.

 
To determine whether thymic cellularity or T cell maturation is affected in the different lckPr-ets2 or lckPr-{Delta}ets2 transgenic mice families, thymi were obtained from both young and adult animals. The morphology of 1-wk-old wild-type (WT) and transgenic thymi was similar (Fig. 3GoA) with the cortex and medulla clearly organized and distinguishable (Fig. 3GoB). However, the expression of {Delta}ets2 in thymi from 1-wk-old animals resulted in reduced cellularity (5-fold decreases in cell numbers compared with WT littermates; Fig. 3GoC) and a partial blockage in maturation specifically at the DN to DP transition (24.3% ± 9.5 DN for lckPr-{Delta}ets2 vs 3.6% ± 1.1 DN for WT; Fig. 3GoD). Fewer T cell numbers were observed in thymi from young lckPr-ets2 transgenic mice compared with those from WT littermates (Fig. 3GoC). The expression of Ets2 in the thymi of young animals had no effect on the maturation of T cells (Fig. 3GoD).



View larger version (58K):
[in this window]
[in a new window]
  		FIGURE 3. The total number of thymic cells from lckPr-{Delta}ets2 transgenic mice is lower and maturation is reduced compared with the total number and maturation of thymic cells from WT or lckPr-ets2 transgenic mice. Seven-day-old animals were sacrificed and T cells were obtained from thymi of the four families of lckPr-ets2 and lckPr-{Delta}ets2 transgenic mice, or WT siblings (wt). A and B, Morphology of thymi from seven-day-old WT and transgenic mice. Photographs of thymi and histological sections of the lobes are visualized. Magnifications are indicated in the figures. C, Thymic cell numbers. Cell numbers were determined using trypan blue exclusion. n, Number of animals from both families used for cellularity and FACS experiments. p, Two-tailed p value using unpaired t test (graph.pad.com) comparing results from transgenic animals to their WT siblings. The p value of 0.02 is statistically significant and of 0.0001 is extremely statistically significant. D, Maturation of lckPr-ets2 and lckPr-{Delta}ets2 transgenic thymocytes at 7 days. Analysis by FACS using CD4 and CD8 Abs showing that only the {Delta}ets2 transgene impedes maturation of CD4-CD8- DN cells toward CD4+CD8+ DP cells. The percentages of DN, DP, or SP cells are indicated as well as their standard errors. The p values were determined as described above. Values of p = 0.2342–1.0000 are not significant, whereas values of 0.0002–0.0006 are extremely significant.

 
Thymic cellularity and maturation were determined for animals as they reached adulthood. Six- to 8-wk-old animals from the four transgenic families were sacrificed, and total numbers of viable T cells from isolated thymi were determined. Although cellularity of lckPr-{Delta}ets2 transgenic animals remained lower when compared with control littermates (2-fold), the differences were considerably reduced with increasing age (compare Fig. 4GoA, 2-fold, with Fig. 3GoC, 5-fold). The partial default in the maturation of DN cells from young lckPr-{Delta}ets2 transgenic animals appeared to be corrected with age, because no differences in T cell maturation was observed in 6- to 8-wk-old lckPr-{Delta}ets2 animals when compared with WT controls (Fig. 4GoB). In addition, the morphology of thymi from adult lckPr-ets2 and lckPr-{Delta}ets2 transgenic mice and WT littermates was similar, with the cortex and medulla regions clearly defined (Fig. 4GoC). Surprisingly, the number of viable T cells from adult lckPr-ets2 transgenic mice was lower than the number of T cells from control littermate thymi (Fig. 4GoA). We hypothesized that the lower number of thymocytes from lckPr-ets2 transgenic mice could be the result of lower proliferative rates, decreased survival, or increased apoptosis of these T cells.



View larger version (34K):
[in this window]
[in a new window]
  		FIGURE 4. The total number of thymic cells is partially recovered and maturation is restored in adult lckPr-{Delta}ets2 transgenic mice. Six- to 8-wk-old animals were sacrificed and T cells were obtained from thymi of the four families of lckPr-ets2 and lckPr-{Delta}ets2 transgenic mice, or WT siblings. A, Cell numbers were determined using trypan blue exclusion. n, Number of animals used for this and FACS experiments. Values of p = 0.0001 are extremely significant. B, Maturation of lckPr-ets2 and lckPr-{Delta}ets2 transgenic thymocytes from adult mice. Analysis by FACS using CD4 and CD8 Abs showing that the {Delta}ets2 transgene no longer impedes maturation of CD4-CD8- DN cells toward CD4+CD8+ DP cells. The percentages of DN, DP, or SP cells are indicated as well as their standard errors. Values of p = 0.1569–1.0000 are not significant, whereas p values of 0.0336–0.0423 are significant. C, Morphology of thymi obtained from adult mice. The histological profile of both the cortex and medulla is similar in thymi obtained from adult lckPr-ets2 and lckPr-{Delta}ets2 transgenic mice and WT littermate mice.

 
To address this question, we first evaluated the effects of Ets2 on in vivo thymocyte proliferation. BrdU was injected i.p. in adult lckPr-ets2 and lckPr-{Delta}ets2 transgenic mice families and control littermates. Animals were sacrificed 4 h later, and thymocytes were obtained, incubated with BrdU Abs, and analyzed by FACS. No difference in proliferation was observed in thymocytes obtained from lckPr-{Delta}ets2 transgenic mice and those obtained from control littermates. Much to our surprise, thymocytes from lckPr-ets2 mice proliferated two times faster than those from WT siblings (Fig. 5Go). Therefore, the reduced thymic cellularity of lckPr-{Delta}ets2 transgenic mice does not appear to be due to a lower proliferative rate.



View larger version (40K):
[in this window]
[in a new window]
  		FIGURE 5. Proliferation of transgenic thymocytes in vivo. Animals were injected i.p. with 1 mg of BrdU. Four hours later, animals were sacrificed and thymocytes were immediately prepared, permeabilized and fixed, labeled with BrdU Abs, and then analyzed by FACS. The second smaller peak (M1) corresponds to thymocytes undergoing DNA synthesis. The FACS analysis visualized here corresponds to one of several experiments, whereas the graph depicts the average of the different independent experiments (n = 4) with standard bars indicated. The p value of 0.0062 is highly statistically significant.

 
To determine the survival of thymocytes from the different transgenic lines compared with their control siblings, the following experiments were performed. The same number of T cells from the four adult lckPr-ets2 and lckPr-{Delta}ets2 transgenic mice families and control littermates were cultured ex vivo in RPMI medium containing 10% FCS, and their viability was assessed by trypan blue exclusion over 72 h (Fig. 6GoA). There was no significant difference in the number of viable thymocytes from lckPr-ets2 transgenic mice compared with thymocytes from control littermates; however, the number of viable thymocytes from lckPr-{Delta}ets2 transgenic mice was significantly lower (Fig. 6GoA). These results indicate that the expression of the dominant negative form of Ets2 does affect the survival of these thymocytes ex vivo. In addition, these results show that the decrease in cellularity of thymi from two different families of adult lckPr-ets2 transgenic mice is not due to decreased survival or increased apoptosis.



View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 6. Survival of transgenic thymocytes ex vivo. A, Cells (1 x 106) isolated from thymi of four lckPr-ets2 and 4 lckPr-{Delta}ets2 transgenic or 4 control (wt) littermate adult mice were cultured in triplicate ex vivo in RPMI 1640 plus 10% FCS. Viable cell numbers were determined using trypan blue exclusion at 3, 6, 21, 30, 48, and 72 h. The number of viable cells were plotted against time and standard errors are indicated. Values of p = 0.080 are not quite statistically significant, yet p values of 0.0022 are very statistically significant. B, Thymi from adult lckPr-ets2 and lckPr-{Delta}ets2 transgenic mice and WT littermates were lysed in Laemmli buffer. Equal amounts of total lysates were subjected to 10% SDS-PAGE, transferred to polyvinylidene difluoride membranes, and incubated with anit-Ets1 and anti-Tubulin Abs. The anti-Tubulin Ab was used as a control for loading and transfer.

 
Ets1 and Ets2 proteins are reciprocally expressed in different thymic subpopulations (12). To exclude the possibility that this mutually exclusive expression is due to Ets2 directly or indirectly down-regulating the expression of Ets1, we investigated the level of Ets1 expression in thymi from lckPr-ets2 and lckPr-{Delta}ets2 transgenic mice and control littermates by Western analysis. As can be seen in Fig. 6GoB, the level of Ets1 remains constant independent of the expression of the ets2 and {Delta}ets2 transgenes.

We previously showed that Ets2 expression protects macrophages from cell death by apoptosis when deprived of a growth factor required for the survival of these cells (6, 20). Glucocorticoid hormones cause rapid depletion of thymocytes by apoptosis (21). Glucocorticoid treatment of normal mice leads to the rapid elimination of cortical CD4+CD8+ DP thymocytes, while mature CD4+ SP or CD8+ SP thymocytes are less sensitive (22). Because endogenous ets2 expression is most abundant in DP thymocytes (13), we chose to target cell death of this subpopulation of T cells using dexamethasone. To assess the effects of Ets2 in protecting thymocytes from glucocorticoid-induced apoptosis in vivo, PBS as a control or dexamethasone was injected into transgenic and control littermate mice. Forty-four hours later, animals were injected with BrdU for 4 h before being sacrificed. Thymocytes were isolated from animals, labeled with BrdU or CD4 and CD8 Abs, and subjected to FACS analyses. The profiles of the different CD4CD8 subpopulations following PBS injections remained identical among lckPr-ets2 and lckPr-{Delta}ets2 transgenic mice and control siblings (data not shown). However, dexamethasone treatment of lckPr-ets2 and lckPr-{Delta}ets2 transgenic mice and WT siblings resulted in inhibited thymic proliferation (Fig. 7GoA compared with Fig. 5Go) and depletion of cells of the CD4+CD8+ DP thymocyte subpopulations (Fig. 7GoB).



View larger version (38K):
[in this window]
[in a new window]
  		FIGURE 7. CD4+ and CD8+ DP subpopulations are lost following a 48-h dexamethasone treatment in vivo. Dexamethasone (2.5 mg) was i.p. injected into mice. Forty-four hours later, 1 mg of BrdU was injected for 4 h. Thymocytes were isolated and labeled with BrdU or CD4 and CD8 Abs. A, No difference in proliferation is observed following a 48-h treatment with dexamethasone (n = 4; p values were not statistically different). B, The different subpopulations are identical following a 48-h treatment of mice with dexamethasone. Graphically represented are five independent experiments (n = 5).

 
It was shown that 50% of thymocytes isolated from mice 6 h after injections with dexamethasone were viable yet programmed to die, as evidenced by annexin V-labeling (Boehringer Ingelheim, Ingelheim, Germany) (23). The result of these experiments led us to investigate the effects of dexamethasone on lckPr-{Delta}ets2 and lckPr-ets2 transgenic mice and their control siblings at this earlier time point. Dexamethasone or PBS was injected i.p. Two hours postinjection, animals were injected with BrdU for 4 h. Animals were then sacrificed, and thymocytes were obtained and labeled with anti-BrdU or with CD4 and CD8 Abs. Although the profile of the CD4CD8 subpopulations is identical in thymocytes obtained from 6-h dexamethasone-treated lckPr-{Delta}ets2 and lckPr-ets2 transgenic mice and their WT siblings and the number of CD4+CD8+ DP cells remained elevated (Fig. 8GoB), clear differences in proliferative rates were observed. The expression of the ets2 transgene allows a higher proliferative rate of 6-h dexamethasone-treated thymocytes (10- to 20-fold, respectively) compared with the proliferation of those thymocytes from dexamethasone-treated control or lckPr-{Delta}ets2 transgenic mice (Fig. 8GoA).



View larger version (38K):
[in this window]
[in a new window]
  		FIGURE 8. Expression of c-Myc correlates with proliferation and the expression of the ets2 transgene following a 6-h in vivo dexamethasone treatment. Dexamethasone (2.5 mg) was injected into animals for 6 h. Two hours postinjection, animals were injected with 1 mg of BrdU as described in Fig. 5Go. Animals were sacrificed, and thymocytes were isolated and labeled with BrdU or CD4 and CD8 Abs or prepared for Western analysis. A, The percentage of BrdU incorporation in thymocytes of lckPr-ets2 transgenic lines was shown to be 20-fold and 10-fold higher than that for lckPr-{Delta}ets2 transgenic mice and WT control siblings, respectively. Forty micrograms of lysates, as determined by the BCA Protein Assay kit (Perbio-Pierce, Rockford, IL) (data not shown), were subjected to 10–15% SDS-PAGE. Following transfer, incubation with anti-c-Myc Abs was performed. Because the Bcl-xL is not regulated upon dexamethasone treatment and its expression parallels protein transfer following coloration, Bcl-xL was used as a control. We arbitrarily set the level of c-Myc to one in lysates from PBS-injected WT animals. The average of fold inductions of c-Myc for all other values are corrected according to Bcl-xL expression. Quantifications were performed using the MacBAS, version 2.2, program. Western analysis indicates that c-Myc expression is up-regulated in thymocytes from lckPr-ets2 transgenic lines. These experiments were repeated four times showing similar results (data not shown). B, The different CD4CD8 compartments were shown by FACS analysis and are graphically represented. No statistical differences were observed in the different experiments (n = 4).

 
Western analysis was performed to identify genes downstream of Ets2 that allow thymocyte proliferation and permit a greater resistance to dexamethasone-induced apoptosis. Two well-characterized anti-apoptotic proteins of the Bcl-2 family have been extensively studied in different thymic populations. Bcl-2 is expressed throughout thymic development except as immature DN thymocytes mature to intermediate DP thymocytes just before positive selection (24, 25) when Bcl-xL becomes abundantly expressed (26). No variation in the level of Bcl-2 expression was observed in thymocytes from the different transgenic families and WT siblings (data not shown). We previously showed that the bcl-x gene can be transcriptionally regulated by Ets2, suggesting that bcl-x would be a good candidate as a target gene (6, 20). Unexpectedly, the level of Bcl-xL remained high and unchanged in lysates obtained from WT and lckPr-ets2 and lckPr-{Delta}ets2 transgenic mice and continued to remain constant even after dexamethasone treatment of the transgenic mice (Fig. 8GoA). Therefore, although bcl-x is a direct target of Ets2 in macrophages, this does not appear to be the case in thymocytes.

The c-Myc protein has been implicated in survival, proliferation and apoptotic processes. Recent studies showed that c-Myc-/- cells fail to proliferate normally at the late DN stage and mature into DP thymocytes (27). In addition, c-Myc was shown to be down-regulated by dexamethasone treatment, and DP thymocytes from c-myc transgenic mice were less susceptible to dexamethasone-induced death (23). Furthermore, c-myc was shown to be a direct target gene of Ets2 (28). Therefore, we asked whether Ets2 expression in lckPr-ets2 transgenic mice resulted in the up-regulation of c-Myc expression. As can be seen in Fig. 8GoA, although in vivo dexamethasone treatment of WT siblings leads to decreases in the levels of c-Myc expression, c-Myc is still abundantly detected in dexamethasone-treated Ets2-expressing thymocytes. These results suggest that the role of Ets2 in proliferation and perhaps a higher resistance to apoptotic signals by corticosteroids may, at least in part, function via a Myc-dependent mechanism. It is worth noting that c-Myc is not down-regulated in dexamethasone-treated lckPr-{Delta}ets2 transgenic animals (1.6 vs 0.2 arbitrary units for WT thymocytes (Fig. 8GoA)) but is up-regulated (1.6 vs 0.3 arbitrary units for PBS-treated thymocytes (Fig. 8GoA)). This suggests that the Ets2 DNA binding domain, perhaps by interacting with coactivators, is sufficient to induce c-Myc expression to a level comparable to that seen in untreated control and lckPr-ets2 transgenic mice. However, this level of expression remains much lower than that observed in thymocytes from dexamethasone-treated lckPr-ets2 transgenic animals (1.6 vs 4 arbitrary units for ets2; Fig. 8GoA). It could be that other Myc-independent pathways are required to induce proliferation of dexamethasone-treated lckPr-{Delta}ets2 transgenic mice. Another possibility, which may not be exclusive of the first, is that c-Myc expression needs to reach a certain level, i.e., comparable to the level of c-Myc in dexamethasone-treated lckPr-ets2 transgenic animals, for the maintenance and/or activation of the proliferation pathway. In any case, although c-Myc is detected in dexamethasone-treated lckPr-{Delta}ets2 transgenic thymocytes, these cells clearly stop proliferating (10.4% BrdU incorporation in thymocytes from PBS-injected lckPr-{Delta}ets2 transgenic mice (Fig. 5Go) vs 1% BrdU incorporation in thymocytes from dexamethasone-injected lckPr-{Delta}ets2 transgenic mice (Fig. 8GoA)).

To determine whether Ets2 expression may be important for thymic cell survival upon apoptotic signals, 1 x 106 thymocytes cultured ex vivo from the four different lckPr-ets2 and lckPr-{Delta}ets2 transgenic mice families and control littermates were treated with dexamethasone during a 48-h period and cell viability was determined by trypan blue exclusion at various time points (Fig. 9Go). Cell viability was greatly affected in lckPr-{Delta}ets2 transgenic thymocytes. Interestingly, the expression of Ets2 appeared to protect thymocytes from glucocorticoid-induced apoptosis as compared with WT littermates. By 21 h, differences in viability were apparent. lckPr-ets2 thymocytes resisted dexamethasone-induced apoptosis better than the T cells from control littermates. Dexamethasone treatment led to a rapid decrease in the number of viable thymocytes from lckPr-{Delta}ets2 transgenic mice. By 48 h, these differences were accentuated.



View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 9. The ets2 transgene protects against dexamethasone-induced apoptosis ex vivo. A, Cells (1 x 106) isolated from thymi of lckPr-ets2 transgenic or control littermate mice were cultured in triplicate ex vivo with 0.1 µM dexamethasone for 48 h. Viable cell numbers were determined using trypan blue exclusion at 3, 6, 21, 30, and 48 h. The total number of viable cells were plotted against time, and standard errors are indicated. Values of p = 0.0035 are very significant, and p values of 0.0001 are extremely significant. B, The ratio of viable cells from dexamethasone-treated thymocytes over nontreated thymocytes (Fig. 6Go) is plotted. Thymocytes from lckPr-ets2 transgenic are the most resistant (values of ~1), and thymocytes from lckPr-{Delta}ets2 transgenic mice are the most susceptible to cell death (values >2).

 
The sensitivity to dexamethasone treatment was determined by calculating the ratio of viability in dexamethasone-treated (Fig. 9GoA) vs nontreated cells (Fig. 6Go). Taking the value of one to indicate insensitivity to dexamethasone, thymocytes from lckPr-ets2 transgenic animals were almost completely resistant to glucocorticoid treatment compared with control littermates (Fig. 9GoB). The greatest sensitivity to dexamethasone was observed in thymocytes from transgenic mice expressing the dominant negative mutant of ets2, {Delta}ets2.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Ets2 is found throughout thymic development with increased mRNA (13) and protein (12) expression at the CD4+CD8+ DP stage. To investigate the function of Ets2 in the thymus, we established transgenic mice expressing Ets2 or a dominant negative mutant, {Delta}Ets2, specifically in the thymus. We showed that Ets2 expression in the thymus results in a lower cellularity but a higher proliferative rate. These seemingly contradictory observations could be explained by a faster T cell migration from the thymus to secondary organs. The lower cellularity most likely cannot be explained by greater apoptosis, because Ets2-expressing thymocytes cultured ex vivo survive in a similar fashion to WT control littermates. Moreover, cells from the thymus of lckPr-ets2 transgenic mice survive much better ex vivo after stimulation with apoptosis-inducing dexamethasone. However, we cannot exclude the possibility that lower cellularity of ets2 transgenic thymi may be the result of TCR-mediated apoptosis, because apoptosis of T lymphocytes mediated by TCR is distinct from that induced by dexamethasone (29), and rapidly proliferating cells, as in the case of ets2 transgenic thymocytes, are more sensitive to TCR-mediated death. Further studies will be needed to clarify this. Therefore, although Ets2 does not appear to be required for thymocyte differentiation, we observe that Ets2 expression allows proliferation and better survival of thymocytes. Finally, we identified that c-Myc, a previously described Ets2 target gene, is activated in Ets2-expressing thymocytes upon dexamethasone treatment. Because c-Myc-/- studies as well as c-Myc transgenic studies show that c-Myc is required for both thymic cell proliferation and for inhibiting dexamethasone-induced apoptosis (23, 27), a likely mechanism is that Ets2 permits T cell proliferation and/or survival via a Myc-dependent pathway.

Thymic development is affected at the DN to DP in young, but not adult, lckPr-{Delta}ets2 transgenic mice. The lower cellularity of thymi from lckPr-{Delta}ets2 is marked in young animals and remains significantly lower as animals reached adulthood. In addition, thymocytes from lckPr-{Delta}ets2 transgenic mice are highly sensitive to cell death by apoptosis simply by cultivating thymocytes ex vivo or by ex vivo treatments with the glucocorticoid, dexamethasone.

Ets1, the founding member of the ets family, is also expressed during T cell development (11, 12). The first studies addressing the role of Ets1 in the thymus used the RAG2-/- complementation assay (14, 15). ES cells containing homozygous mutations of the ets1 gene were produced and injected into RAG2-deficient blastocysts to generate chimeric mice. The absence of Ets1 in these chimeric animals resulted in T cell maturation and T cell activation defects. However, once the Ets1-/- mouse was generated, although cellularity of the thymus was often reduced, no differences in the relative proportions of DP CD4+CD8- or SP CD8+ CD4- were observed (9) suggesting that maturation defects were either a result of the RAG2-/- complementation system or somehow compensated in Ets1-/- mice. We observe a default in maturation in young animals expressing a {Delta}ets2 transgene. Not only has {Delta}Ets2 been shown to functionally compete with endogenous Ets1 and Ets2 proteins in binding to their specific Ets binding sites, {Delta}Ets2 binds more efficiently to ets binding sites than full-length Ets2 or Ets1 proteins (reviewed in Ref. 5). Although both ets1 and ets2 transcripts are detected in a similar manner throughout T cell development, the expression of Ets1 and Ets2 proteins has been shown to be mutually exclusive. Ets1 is specifically expressed in DN and in resting CD4+ and CD8+ SP thymic subsets, whereas Ets2 expression is limited to DP T cells (12, 30). Because the expression of the {Delta}ets2 transgene is under the control of the lck promoter, which becomes active at the DN to DP transition, {Delta}Ets2 specifically interferes with endogenous Ets2, but not Ets1, in the CD4+CD8+ DP population although {Delta}Ets2 could compete with Ets1 in CD4-CD8- DN T cells. Because the maturation defect of lckPr-{Delta}ets2 transgenic mice at the DN to DP transition is corrected with the age of the animal, most likely other redundant pathways compensate for the loss of activation by Ets2 and Ets1.

Simply cultivating thymocytes from RAG2-/-Ets1-/- chimeric mice ex vivo led to increased susceptibility to cell death of these cells (14, 15). Interestingly, we observe that thymocytes from lckPr-{Delta}ets2 transgenic mice cultivated ex vivo are highly sensitive to cell death and thymocytes from dexamethasone-treated lckPr-ets2 transgenic mice are more resistant to apoptosis. These results show that both Ets proteins function in cell survival rather than being required for T cell maturation.

Transgenic studies have shown that the antiapoptotic protein Bcl-xL inhibited death after dexamethasone, gamma-irradiation, and anti-CD3 treatment (31). Several transcription factor families have been described as regulating the transcription of the bcl-x gene (32) including Ets transcription factors (6, 20). Surprisingly, Ets2 expression in transgenic mice had no effect on Bcl-xL levels. Two possibilities that could explain this apparent discrepancy exist. First, we showed (20) that a clear synergy exists between Ets2 and another Ets family member, PU.1, in transactivating the bcl-x promoter first described by Grillot et al. (33). Because PU.1 is not expressed in thymic cells (13), no such synergy could exist to regulate this region of the bcl-x gene. Second, other bcl-x promoter regions have recently been identified and shown to be active with different tissue specificities (34, 35). It is possible that, although the promoter region originally identified by Grillot is active in a T cell line, it may not be active in primary thymocytes. Furthermore, although Bcl-xL may inhibit dexamethasone-induced apoptosis in transgenic mice (31), endogenous expression of Bcl-xL remains constant even after dexamethasone treatment of WT and lckPr-ets2 and lckPr-{Delta}ets2 transgenic mice, in agreement with similar results obtained by Wang et al. (23) using dexamethasone-treated BALB/c mice.

The c-Myc transcription factor is associated with cell proliferation and its deregulation is associated with different types of cancers including leukemias and lymphomas. Recent studies showed that c-Myc-/- cells fail to proliferate normally at the late DN stage and mature into DP thymocytes (27). Interestingly, c-Myc was shown to be a direct target of Ets2 (28). c-Myc can induce apoptosis upon certain apoptotic signals, but c-Myc can also inhibit apoptosis. In the murine WEHI-231 B cells, c-Myc expression renders the cells resistant to anti-Ig-mediated apoptosis (36). c-Myc is down-regulated upon dexamethasone treatment of BALB/c animals, and c-Myc renders transgenic animals less sensitive to glucocorticoid-induced cell death (23). These studies, which used transgenic mice expressing c-Myc under the control of a mouse mammary tumor virus dexamethasone-inducible promoter/enhancer, showed that, although Myc prolongs survival, c-Myc is not sufficient to completely abrogate the effects of dexamethasone-induced cell death. We observe that Ets2 expression in lckPr-ets2 transgenic mice allows greater resistance to dexamethasone as evidenced by a high proliferative rate and that c-Myc expression remains high when compared with that of lckPr-{Delta}ets2 transgenic or control littermates where c-Myc expression is considerably lower.

Ets2 is expressed in a variety of tissues and cell types, and, although many potential target genes have been identified (reviewed in Ref. 37), little is known about the function of Ets2 in vivo. Disruption of the ets2 gene is early-embryonic lethal due to a trophoblast default demonstrating that Ets2 is essential for placenta function (8). Transgenic animal studies have implicated Ets2 in bone formation (38) and in macrophage development (39). The presence of Ets2 throughout thymic development suggested a role of this protein in this organ. Using transgenic approaches, we showed that, although Ets2 expression may participate in the maturation of thymocytes, Ets expression clearly permits T cells to proliferate and survive, and we propose that Ets2, via activation of c-Myc, may be required for permitting proliferation and reducing cell death upon apoptotic signals.


   Acknowledgments
 
We thank Drs. R. M. Perlmutter and S. W. Henning for providing the p1017 vector, Dr. M. Rassoulzadegan for microinjections to generate one family of lckPr-{Delta}ets2 mice, M. Radjkumar for preparation of mouse-tail DNAs and slot blots, and E. Couchi for excellent animal care. We also thank M. Magliano for helpful suggestions during the histological preparations.


   Footnotes
 
1 K.E.B. was supported by Grant 5231 from the Association pour la Recherche contre le Cancer. A.Z. and F.C. were supported by le Ministere de l’Education Nationale, de la Recherche, et de la Technologie. Back

2 Address correspondence and reprint requests to Dr. Kim E. Boulukos, Center de Biochimie, Université de Nice, Parc Valrose, 06108 cedex, Nice, France. E-mail address: boulukos{at}unice.fr Back

3 Abbreviations used in this paper: DN, double negative; DP, double positive; SP, single positive; BrdU, 5-bromo-2'-deoxyuridine; WT, wild type; RAG, recombination-activating gene; sc, Santa Cruz. Back

Received for publication July 18, 2001. Accepted for publication August 19, 2002.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Boulukos, K. E., P. Pognonec, A. Begue, J. C. Gesquière, D. Stéhelin, J. Ghysdael. 1988. Identification in chickens of an evolutionarily conserved cellular ets-2 gene (c-ets-2) encoding nuclear proteins related to the products of the c-ets proto-oncogene. EMBO J. 7:697.[Medline]
  2. Watson, D. K., M. J. McWilliams, P. Lapis, J. A. Lautenberger, C. W. Schweinfest, T. S. Papas. 1988. Mammalian ets-1 and ets-2 genes encode highly conserved proteins. Proc. Natl. Acad. Sci. USA 85:7862.[Abstract/Free Full Text]
  3. Leprince, D., A. Gegonne, J. Coll, C. DeTaisne, A. Schneeberger, C. Lagrou, D. Stéhelin. 1983. A putative second cell-derived oncogene of the avian leukemia retrovirus E26. Nature 306:395.[Medline]
  4. Nunn, M. F., P. M. Seeburg, C. Moscovici, P. H. Duesberg. 1983. Tripartite structure of the avian erythroblastosis virus E26 transforming gene. Nature 306:391.[Medline]
  5. Ghysdael, J., A. Boureux. 1997. The ETS family of transcriptional regulators. M. Yaniv, and J. Ghysdael, eds. In Oncogenes as Transcriptional Regulators: Retroviral Oncogenes Vol. 1:29. Birkhauser, Basel.
  6. Sevilla, L., C. Aperlo, V. Dulic, J. C. Chambard, C. Boutonnet, O. Pasquier, P. Pognonec, K. E. Boulukos. 1999. The Ets2 transcription factor inhibits apoptosis induced by CSF-1 deprivation of macrophages through a Bcl-xL-dependent mechanism. Mol. Cell. Biol. 19:2624.[Abstract/Free Full Text]
  7. Ohtani, N., Z. Zebedee, T. Huot, J. Stinson, M. Sugimoto, Y. Ohashi, A. Sharrocks, G. Peters, E. Hara. 2001. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature 409:1067.[Medline]
  8. Yamamoto, H., M. L. Flannery, S. Kupriyanov, J. Pearce, S. R. McKercher, G. W. Henkel, R. A. Maki, Z. Werb, R. G. Oshima. 1998. Defective trophoblast function in mice with a targeted mutation of Ets2. Genes Dev. 12:1315.[Abstract/Free Full Text]
  9. Barton, K., N. Muthusamy, C. Fischer, C.-N. Ting, T. L. Walunas, L. L. Lanier, J. M. Leiden. 1998. The Ets1 transcription factor is required for the development of natural killer cells in mice. Immunity 9:555.[Medline]
  10. Walunas, T. L., B. Wang, C. R. Wang, J. M. Leiden. 2000. Cutting edge: the Ets1 transcription factor is required for the development of NK T cells in mice. J. Immunol. 164:2857.[Abstract/Free Full Text]
  11. Pognonec, P., K. E. Boulukos, J. C. Gesquière, D. Stéhelin, J. Ghysdael. 1988. Mitogenic stimulation of thymocytes results in the calcium-dependent phosphorylation of c-Ets-1 proteins. EMBO J. 7:977.[Medline]
  12. Bhat, N. K., K. L. Komschlies, S. Fujiwara, R. J. Fisher, B. J. Mathieson, T. A. Gregorio, H. A. Young, J. W. Kasik, K. Ozato, T. S. Papas. 1989. Expression of ets genes in mouse thymocyte subsets and T cells. J. Immunol. 142:672.[Abstract]
  13. Anderson, M. K., G. Hernandez-Hoyos, R. A. Diamond, E. V. Rothenberg. 1999. Precise developmental regulation of Ets family transcription factors during specification and commitment to the T cell lineage. Development 126:3131.[Abstract]
  14. Bories, J. C., D. M. Willerford, D. Grevin, L. Davidson, A. Camus, P. Martin, D. Stehelin, F. W. Alt. 1995. Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the ets-1 proto-oncogene. Nature 377:635.[Medline]
  15. Muthusamy, N., K. Barton, J. M. Leiden. 1995. Defective activation and survival of T cells lacking the ets-1 transcription factor. Nature 377:639.[Medline]
  16. Chaffin, K. E., C. R. Beals, T. M. Wilkie, K. A. Forbush, M. I. Simon, R. M. Perlmutter. 1990. Dissection of thymocyte signaling pathways by in vivo expression of pertussis toxin ADP-ribosyltransferase. EMBO J. 9:3821.[Medline]
  17. Langer, S. J., D. M. Bortner, M. F. Roussel, C. J. Sherr, M. C. Ostrowski. 1992. Mitogenic signaling by colony-stimulating factor 1 and Ras is suppressed by the ets-2 DNA-binding domain and restored by myc overexpression. Mol. Cell. Biol. 12:5355.[Abstract/Free Full Text]
  18. Boulukos, K. E., P. Pognonec. 2001. MICE, a program to track and monitor animals in animal facilities. BMC Genet. 2:4.[Medline]
  19. Sohn, S., K. Forbush, X. Pan, R. Perlmutter. 2001. Activated p56lck directs maturation of both CD4 and CD8 single-positive thymocytes. J. Immunol. 166:2209.[Abstract/Free Full Text]
  20. Sevilla, L., A. Zaldumbide, F. Carlotti, M. A. Dayem, P. Pognonec, K. E. Boulukos. 2001. Bcl-xL expression correlates with primary macrophage differentiation, activation of functional competence and survival, and results from synergistic transcriptional activation by Ets2 and PU.1. J. Biol. Chem. 276:17800.[Abstract/Free Full Text]
  21. Wylie, A.. 1980. Glucocorticoid-induced thymic apoptosis is associated with endogenous nuclease activation. Nature 284:555.[Medline]
  22. Screpanti, I., S. Morrone, D. Meco, A. Santoni, A. Gulino, R. Paolini, A. Crisanti, B. J. Mathieson, L. Frati. 1989. Steroid sensitivity of thymocyte subpopulations during intrathymic differentiation: effects of 17 {beta}-estradiol and dexamethasone on subsets expressing T cell antigen receptor or IL-2 receptor. J. Immunol. 142:3378.[Abstract]
  23. Wang, W., J. Wykrzykowska, T. Johnson, R. Sen, J. Sen. 1999. A NF-{kappa}B/c-myc-dependent survival pathway is targeted by corticosteroids in immature thymocytes. J. Immunol. 162:314.[Abstract/Free Full Text]
  24. Veis, D., C. L. Sentman, E. Bach, S. J. Korsmeyer. 1993. Expression of the Bcl-2 protein in murine and human thymocytes and peripheral T lymphocytes. J. Immunol. 151:2546.[Abstract]
  25. Linette, G. P., M. J. Grusby, S. M. Hedrick, T. H. Hansen, L. H. Glimcher, S. J. Korsmeyer. 1994. Bcl-2 is upregulated at the CD4+CD8+ stage during positive selection and promotes thymocyte differentiation at several control points. Immunity 1:197.[Medline]
  26. Grillot, D. A. M., R. Merino, G. Nunez. 1995. Bcl-xL displays restricted distribution during T cell development and inhibits multiple forms of apoptosis but not clonal deletion in transgenic mice. J. Exp. Med. 182:1973.[Abstract/Free Full Text]
  27. Douglas, N. C., H. Jacobs, A. L. M. Bothwell, A. C. Hayday. 2001. Defining the specific physiological requirements for c-Myc in T cell development. Nat. Immunol. 2:307.[Medline]
  28. Roussel, M. F., J. N. Davis, J. L. Cleveland, J. Ghysdael, S. W. Hiebert. 1994. Dual control of myc expression through a single DNA binding site targeted by ETS family proteins and E2F-1. Oncogene 9:405.[Medline]
  29. Zacharchuk, C., M. Mercep, P. Chakraborti, S. S. Simons, Jr, J. Ashwell. 1990. Programmed T lymphocyte death: cell activation- and steroid-induced pathways are mutually antagonistic. J. Immunol. 145:4037.[Abstract]
  30. Bhat, N. K., C. B. Thompson, T. Lindsten, C. H. June, S. Fujiwara, S. Koizumi, R. J. Fisher, T. S. Papas. 1990. Reciprocal expression of human ETS1 and ETS2 genes during T-cell activation. Proc. Natl. Acad. Sci. USA 87:3723.[Abstract/Free Full Text]
  31. Chao, D., S. J. Korsmeyer. 1997. Bcl-xL-regulated apoptosis in T cell development. Int. Immunol. 9:1375.[Abstract/Free Full Text]
  32. Sevilla, L., A. Zaldumbide, P. Pognonec, K. E. Boulukos. 2001. Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel/NF{kappa}B, STAT and AP1 transcription factor families. Histol. Histopathol. 16:595.[Medline]
  33. Grillot, D. A., M. Gonzalez-Garcia, D. Ekhterae, L. Duan, N. Inohara, S. Ohta, M. F. Seldin, G. Nunez. 1997. Genomic organization, promoter region analysis, and chromosome localization of the mouse bcl-x gene. J. Immunol. 158:4750.[Abstract]
  34. MacCarthy-Morrogh, L., L. Wood, M. Brimmell, P. Johnson, G. Packham. 2000. Identification of a novel human BCL-X promoter and exon. Oncogene 19:5534.[Medline]
  35. Pecci, A., L. Rocha-Viegas, J. L. Baranao, M. Beato. 2001. Promoter choice influences alternative splicing and determines the balance of isoforms expressed from the mouse bcl-x gene. J. Biol. Chem. 276:21062.[Abstract/Free Full Text]
  36. Wu, M., M. Arsura, R. E. Bellas, M. J. FitzGerald, H. Lee, S. I. Schauer, D. H. Sherr, G. E. Sonenshein. 1996. Inhibition of c-myc expression induces apoptosis of WEHI 231 murine B cells. Mol. Cell. Biol. 16:5015.[Abstract]
  37. Sementchenko, V., D. Watson. 2000. Ets target genes: past, present and future. Oncogene 19:6533.[Medline]
  38. Sumarsono, S. H., T. Wilson, M. J. Tymms, D. J. Venter, C. M. Corrick, R. Kola, M. H. Lahoud, T. S. Papas, A. Seth, I. Kola. 1996. Down’s syndrome-like skeletal abnormalities in Ets2 transgenic mice. Nature 379:534.[Medline]
  39. Jin, D. I., S. B. Jameson, M. A. Reddy, D. Schenkman, M. C. Ostrowski. 1995. Alterations in differentiation and behavior of monocytic phagocytes in transgenic mice that express dominant suppressors of ras signaling. Mol. Cell. Biol. 15:693.[Abstract]



This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
Z. Shi, Z. Cai, S. Wen, C. Chen, C. Gendron, A. Sanchez, K. Patterson, S. Fu, J. Yang, D. Wildman, et al.
Transcriptional Regulation of the Novel Toll-like Receptor Tlr13
J. Biol. Chem., July 31, 2009; 284(31): 20540 - 20547.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Kawagoe and G. C. Grosveld
MN1-TEL myeloid oncoprotein expressed in multipotent progenitors perturbs both myeloid and lymphoid growth and causes T-lymphoid tumors in mice
Blood, December 15, 2005; 106(13): 4278 - 4286.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
F. Takeshita, K. Suzuki, S. Sasaki, N. Ishii, D. M. Klinman, and K. J. Ishii
Transcriptional Regulation of the Human TLR9 Gene
J. Immunol., August 15, 2004; 173(4): 2552 - 2561.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
I. Schmitz, L. K. Clayton, and E. L. Reinherz
Gene expression analysis of thymocyte selection in vivo
Int. Immunol., October 1, 2003; 15(10): 1237 - 1248.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. Leider and D. Melamed
Differential c-Myc Responsiveness to B Cell Receptor Ligation in B Cell-Negative Selection
J. Immunol., September 1, 2003; 171(5): 2446 - 2452.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zaldumbide, A.
Right arrow Articles by Boulukos, K. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zaldumbide, A.
Right arrow Articles by Boulukos, K. E.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS